Recent News for RGEN - Repligen Corporation

Date Title
Apr 13 Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study
Apr 13 Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study
Apr 12 Repligen: A Picks-And-Shovels Play On Biological Therapy Growth
Apr 12 These 4 Measures Indicate That Repligen (NASDAQ:RGEN) Is Using Debt Safely
Apr 9 Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer Study
Apr 9 Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF
Apr 7 Is RGEN Stock A Buy or Sell?
Apr 6 Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA
Apr 6 ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down
Apr 5 Supernus (SUPN) Receives FDA Approval for ADHD Treatment
Apr 1 Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD
Apr 1 3 Overlooked Healthcare Stocks to Buy Right Now
Mar 30 Encompass Health (EHC) Opens Hospital, Boosts Texas Presence
Mar 30 Incyte (INCY) Gets EU Nod for Cholangiocarcinoma Drug Pemazyre
Mar 28 3 Disruptive Stocks to Buy and Hold for the Next Decade
Mar 26 Why Is Repligen (RGEN) Down 12.9% Since Last Earnings Report?
Mar 25 Is Repligen (RGEN) a Great Growth Stock?
Mar 19 Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UC
Mar 17 Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
Mar 9 Ultragenyx's (RARE) IND for mRNA Therapy, UX053 Cleared by FDA
Mar 9 ACADIA (ACAD) Falls as FDA Finds Deficiencies in Nuplazid sNDA
Mar 8 Is Repligen Corporation (RGEN) A Smart Long-Term Buy?
Mar 3 Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails
Mar 3 Repligen Corporation to Present at Barclays Global Healthcare Conference
Mar 2 Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates
Back to the Main RGEN Page...